{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:43:40Z","timestamp":1787690620564,"version":"build-2784847793"},"reference-count":115,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.schres.2012.06.020","type":"journal-article","created":{"date-parts":[[2012,7,23]],"date-time":"2012-07-23T21:00:54Z","timestamp":1343077254000},"page":"204-213","source":"Crossref","is-referenced-by-count":141,"title":["Immunomodulatory effects of clozapine and their clinical implications: What have we learned so far?"],"prefix":"10.1016","volume":"140","author":[{"given":"Rasmus","family":"R\u00f8ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarne K.","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian R.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmi","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.schres.2012.06.020_bb0005","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4088\/JCP.v57n1205","article-title":"Predictive value of eosinophilia for neutropenia during clozapine treatment","volume":"57","author":"Ames","year":"1996","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2012.06.020_bb0010","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4088\/JCP.09m05527yel","article-title":"Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis","volume":"72","author":"Athanasiou","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2012.06.020_bb0015","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1192\/bjp.169.4.483","article-title":"Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland","volume":"169","author":"Atkin","year":"1996","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.06.020_bb0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1192\/bjp.171.1.90b","article-title":"Clozapine treatment, eosinophilia and agranulocytosis","volume":"171","author":"Bailey","year":"1997","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0025","first-page":"92","article-title":"Case report: acute pancreatitis induced by clozapine","volume":"68","author":"Bayard","year":"2005","journal-title":"Acta Gastroenterol. Belg."},{"issue":"2","key":"10.1016\/j.schres.2012.06.020_bb0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1055\/s-2007-979197","article-title":"Asymptomatic pancreatitis associated with clozapine","volume":"32","author":"Bergemann","year":"1999","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"10.1016\/j.schres.2012.06.020_bb0035","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.pnpbp.2007.03.009","article-title":"High clozapine concentrations in leukocytes in a patient who developed leukocytopenia","volume":"31","author":"Bergemann","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cytogfr.2007.10.004","article-title":"Dendritic cells and cytokines in human inflammatory and autoimmune diseases","volume":"19","author":"Blanco","year":"2008","journal-title":"Cytokine Growth Factor Rev."},{"issue":"6","key":"10.1016\/j.schres.2012.06.020_bb0045","first-page":"259","article-title":"Triad of hyperthermia, increased REM sleep, and cataplexy during clozapine treatment?","volume":"51","author":"Blum","year":"1990","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0050","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/00048674.2010.533365","article-title":"Successful clozapine rechallenge after acute myocarditis","volume":"45","author":"Bray","year":"2011","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.schres.2012.06.020_bb0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.schres.2007.07.018","article-title":"Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study","volume":"97","author":"Byrne","year":"2007","journal-title":"Schizophr. Res."},{"issue":"2\u20133","key":"10.1016\/j.schres.2012.06.020_bb0065","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.schres.2008.08.030","article-title":"Elevated serum levels of tumor necrosis factor-\u03b1 in clozapine-associated obesity in chronic schizophrenia","volume":"106","author":"Chen","year":"2008","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.schres.2012.06.020_bb0070","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1182\/blood.V86.10.3835.bloodjournal86103835","article-title":"The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups","volume":"86","author":"Corzo","year":"1995","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.schres.2012.06.020_bb0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/026988110101500306","article-title":"Antipsychotic drugs result in the formation of immature neutrophil leucocytes in schizophrenic patients","volume":"15","author":"Delieu","year":"2001","journal-title":"J. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.schres.2012.06.020_bb0080","first-page":"882","article-title":"In vitro effect of clozapine on hemopoietic progenitor cells","volume":"83","author":"Deliliers","year":"1998","journal-title":"Haematologica"},{"key":"10.1016\/j.schres.2012.06.020_bb0090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00008571-200103000-00004","article-title":"Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry","volume":"11","author":"Dettling","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"5","key":"10.1016\/j.schres.2012.06.020_bb0085","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/sj.tpj.6500423","article-title":"Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens","volume":"7","author":"Dettling","year":"2007","journal-title":"Pharmacogenomics J."},{"issue":"9206","key":"10.1016\/j.schres.2012.06.020_bb0095","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0140-6736(00)00035-0","article-title":"Clozapine and sudden death","volume":"355","author":"Devarajan","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.schres.2012.06.020_bb0100","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bbi.2006.02.002","article-title":"Cytokines in schizophrenia and the effects of antipsychotic drugs","volume":"20","author":"Drzyzga","year":"2006","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2012.06.020_bb0585","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1192\/bjp.188.3.255","article-title":"Rechallenge with clozapine following leucopenia or neutropenia during previous therapy","volume":"188","author":"Dunk","year":"2006","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2012.06.020_bb0110","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1176\/appi.ajp.163.3.521","article-title":"Association of schizophrenia and autoimmune diseases: linkage of Danish national registers","volume":"163","author":"Eaton","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2012.06.020_bb0115","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.psc.2007.04.001","article-title":"Treatment-resistant schizophrenia","volume":"30","author":"Elkis","year":"2007","journal-title":"Psychiatr. Clin. North Am."},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0590","first-page":"CD000059","article-title":"Clozapine versus typical neuroleptic medication for schizophrenia","author":"Essali","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2012.06.020_bb0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hup.917","article-title":"Haematological toxicity of drugs used in psychiatry","volume":"23","author":"Flanagan","year":"2008","journal-title":"Hum. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2012.06.020_bb0130","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0026-895X(24)13268-3","article-title":"A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes","volume":"53","author":"Gardner","year":"1998","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.schres.2012.06.020_bb0135","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/026988110201600419","article-title":"The development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after treatment with clozapine in schizophrenia: implications for clinical care, recognition and management","volume":"16","author":"Garlipp","year":"2002","journal-title":"J. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.schres.2012.06.020_bb0140","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1176\/appi.ajp.2008.07111823","article-title":"Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia","volume":"165","author":"Ghaznavi","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0145","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0300-483X(98)00110-3","article-title":"Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis","volume":"131","author":"Guest","year":"1998","journal-title":"Toxicology"},{"issue":"5","key":"10.1016\/j.schres.2012.06.020_bb0150","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0022-3956(99)00021-7","article-title":"Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis","volume":"33","author":"Haack","year":"1999","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00002018-200730010-00005","article-title":"Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993\u20132003","volume":"30","author":"Haas","year":"2007","journal-title":"Drug Saf."},{"issue":"3","key":"10.1016\/j.schres.2012.06.020_bb0160","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.toxlet.2010.02.006","article-title":"The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing","volume":"194","author":"Haglund","year":"2010","journal-title":"Toxicol. Lett."},{"issue":"10","key":"10.1016\/j.schres.2012.06.020_bb0165","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jpsychires.2011.04.009","article-title":"Impact of antipsychotics on cytokine production in-vitro","volume":"45","author":"Himmerich","year":"2011","journal-title":"J. Psychiatr. Res."},{"issue":"Suppl. 3","key":"10.1016\/j.schres.2012.06.020_bb0170","first-page":"3","article-title":"Reducing clozapine-related morbidity and mortality: 5years of experience with the Clozaril National Registry","volume":"59","author":"Honigfeld","year":"1998","journal-title":"J. Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2012.06.020_bb0175","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2337\/diabetes.43.11.1271","article-title":"Tumor necrosis factor alpha: a key component of the obesity\u2013diabetes link","volume":"43","author":"Hotamisligil","year":"1994","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.schres.2012.06.020_bb0180","first-page":"429","article-title":"Clozapine-induced transient white blood count disorders","volume":"55","author":"Hummer","year":"1994","journal-title":"J. Clin. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.schres.2012.06.020_bb0185","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF02245622","article-title":"Does eosinophilia predict clozapine induced neutropenia?","volume":"124","author":"Hummer","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.schres.2012.06.020_bb0190","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.taap.2006.01.008","article-title":"Increased FasL expression correlates with apoptotic changes in granulocytes cultured with oxidized clozapine","volume":"214","author":"Husain","year":"2006","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"7","key":"10.1016\/j.schres.2012.06.020_bb0195","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.pnpbp.2011.05.011","article-title":"Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders","volume":"35","author":"Igue","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2012.06.020_bb0200","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1021\/tx100035k","article-title":"Effect of clozapine on neutrophil kinetics in rabbits","volume":"23","author":"Iverson","year":"2010","journal-title":"Chem. Res. Toxicol."},{"issue":"1\u20132","key":"10.1016\/j.schres.2012.06.020_bb0205","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0920-9964(01)00262-6","article-title":"The characteristics of clozapine-induced fever","volume":"56","author":"Jeong","year":"2002","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2012.06.020_bb0595","first-page":"CD003082","article-title":"Haloperidol versus placebo for schizophrenia","volume":"2001","author":"Joy","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.schres.2012.06.020_bb0600","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1600-0447.1985.tb01268.x","article-title":"Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12years","volume":"71","author":"Juul-Povlsen","year":"1985","journal-title":"Acta Psychiatr. Scand."},{"issue":"9","key":"10.1016\/j.schres.2012.06.020_bb0220","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2012.06.020_bb0225","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hup.779","article-title":"Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS?","volume":"21","author":"Kang","year":"2006","journal-title":"Hum. Psychopharmacol."},{"issue":"9193","key":"10.1016\/j.schres.2012.06.020_bb0230","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(99)10385-4","article-title":"Myocarditis and cardiomyopathy associated with clozapine","volume":"354","author":"Kilian","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0235","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.psyneuen.2008.08.016","article-title":"Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever","volume":"34","author":"Kluge","year":"2009","journal-title":"Psychoneuroendocrinology"},{"issue":"9","key":"10.1016\/j.schres.2012.06.020_bb0240","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1592\/phco.23.10.1123.32759","article-title":"Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports","volume":"23","author":"Koller","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0605","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00004714-200102000-00002","article-title":"Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia","volume":"21","author":"Lahdelma","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2012.06.020_bb0250","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/JCP.0b013e3181e6a082","article-title":"Clozapine is cytotoxic to primary cultures of human bone marrow mesenchymal stromal cells","volume":"30","author":"Lahdelma","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9657","key":"10.1016\/j.schres.2012.06.020_bb0255","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0260","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0162-3109(97)00037-4","article-title":"Short and long-term immunosuppressive effects of clozapine and haloperidol","volume":"37","author":"Leykin","year":"1997","journal-title":"Immunopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0270","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF01064682","article-title":"Clinical profile of clozapine: adverse reactions and agranulocytosis","volume":"63","author":"Lieberman","year":"1992","journal-title":"Psychiatr. Q."},{"issue":"5","key":"10.1016\/j.schres.2012.06.020_bb0265","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.npp.1300157","article-title":"Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine","volume":"28","author":"Lieberman","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.schres.2012.06.020_bb0280","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/JCP.0b013e3181eeb7f7","article-title":"Clozapine mobilizes CD34(+) hematopoietic stem and progenitor cells and increases plasma concentration of interleukin 6 in patients with schizophrenia","volume":"30","author":"L\u00f6ffler","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2012.06.020_bb0285","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/YIC.0b013e32833643fd","article-title":"Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients","volume":"25","author":"L\u00f6ffler","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"10","key":"10.1016\/j.schres.2012.06.020_bb0275","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1345\/aph.1K126","article-title":"Characterization and clinical management of clozapine-induced fever","volume":"41","author":"Lowe","year":"2007","journal-title":"Ann. Pharmacother."},{"issue":"5","key":"10.1016\/j.schres.2012.06.020_bb0290","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0447.1994.tb01527.x","article-title":"Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine","volume":"89","author":"Maes","year":"1994","journal-title":"Acta Psychiatr. Scand."},{"issue":"2\u20133","key":"10.1016\/j.schres.2012.06.020_bb0300","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0920-9964(97)00057-1","article-title":"In vivo immunomodulatory effects of clozapine in schizophrenia","volume":"26","author":"Maes","year":"1997","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.schres.2012.06.020_bb0305","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0022-3565(25)12206-4","article-title":"The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man","volume":"275","author":"Maggs","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2\u20133","key":"10.1016\/j.schres.2012.06.020_bb0310","first-page":"180","article-title":"When can patients with potentially life-threatening adverse effects be rechallenged with clozapine?","volume":"134","author":"Manu","year":"2012","journal-title":"A systematic review of the published literature. Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2012.06.020_bb0315","first-page":"176","article-title":"Dopamine selectively modulates lipopolysaccharide-induced TNF-alpha, IFN-gamma and IL-10 within mice tissues","volume":"32","author":"Matalka","year":"2011","journal-title":"Neuro Endocrinol. Lett."},{"issue":"10","key":"10.1016\/j.schres.2012.06.020_bb0320","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1001\/archpsyc.1989.01810100098019","article-title":"Effects of short-term administration of antipsychotic drugs on lymphocyte subsets in schizophrenic patients","volume":"46","author":"McAllister","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0325","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/01.jcp.0000150217.51433.9f","article-title":"Adverse cardiac effects associated with clozapine","volume":"25","author":"Merrill","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.schres.2012.06.020_bb0330","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1586\/14737175.7.7.829","article-title":"Cardiovascular effects of antipsychotics","volume":"7","author":"Michelsen","year":"2007","journal-title":"Expert. Rev. Neurother."},{"issue":"7","key":"10.1016\/j.schres.2012.06.020_bb0335","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2012.06.020_bb0340","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1440-1819.2009.01945.x","article-title":"Cytokines and schizophrenia: microglia hypothesis of schizophrenia","volume":"63","author":"Monji","year":"2009","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0345","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0165-1781(97)00036-X","article-title":"Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment","volume":"71","author":"Monteleone","year":"1997","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.schres.2012.06.020_bb0350","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/WNF.0b013e318197a2f2","article-title":"Clozapine-induced serositis: review of its clinical features, pathophysiology and management strategies","volume":"32","author":"Mouaffak","year":"2009","journal-title":"Clin. Neuropharmacol."},{"issue":"6","key":"10.1016\/j.schres.2012.06.020_bb0355","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1600-0447.2009.01392.x","article-title":"Last episode psychosis","volume":"119","author":"Munk-J\u00f8rgensen","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.schres.2012.06.020_bb0385","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/schbul\/sbq137","article-title":"Risk factors for ileus in patients with schizophrenia","volume":"38","author":"Nielsen","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"2\u20133","key":"10.1016\/j.schres.2012.06.020_bb0380","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.schres.2010.08.035","article-title":"Clozapine treatment associated with increased risk of acute myeloid leukemia (AML)","volume":"123","author":"Nielsen","year":"2010","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.schres.2012.06.020_bb0370","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.euroneuro.2009.03.002","article-title":"Increased use of antibiotics in patients treated with clozapine","volume":"19","author":"Nielsen","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.schres.2012.06.020_bb0360","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/0269881108100320","article-title":"Psychiatrists' attitude towards and knowledge of clozapine treatment","volume":"24","author":"Nielsen","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.schres.2012.06.020_bb0375","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/npp.2010.78","article-title":"Antipsychotics associated with the development of type 2 diabetes in antipsychotic-na\u00efve schizophrenia patients","volume":"35","author":"Nielsen","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.schres.2012.06.020_bb0365","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0447.2011.01710.x","article-title":"Optimizing clozapine treatment","volume":"123","author":"Nielsen","year":"2011","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0395","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nri702","article-title":"Cytokines and autoimmunity","volume":"2","author":"O'Shea","year":"2002","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.schres.2012.06.020_bb0390","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2217\/14622416.9.8.1101","article-title":"Clozapine-induced agranulocytosis and its genetic determinants","volume":"9","author":"Opgen-Rhein","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.schres.2012.06.020_bb0400","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbr.2008.12.016","article-title":"Immune involvement in schizophrenia and autism: etiology, pathology and animal models","volume":"204","author":"Patterson","year":"2009","journal-title":"Behav. Brain Res."},{"issue":"6","key":"10.1016\/j.schres.2012.06.020_bb0410","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.bcp.2006.06.006","article-title":"Clozapine bioactivation induces dose-dependent, drug-specific toxicity of human bone marrow stromal cells: a potential in vitro system for the study of agranulocytosis","volume":"72","author":"Pereira","year":"2006","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.schres.2012.06.020_bb0405","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/sj.tpj.6500179","article-title":"Potential clozapine target sites on peripheral hematopoietic cells and stromal cells of the bone marrow","volume":"3","author":"Pereira","year":"2003","journal-title":"Pharmacogenomics J."},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0415","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-2006-931475","article-title":"In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU)","volume":"39","author":"Pessina","year":"2006","journal-title":"Pharmacopsychiatry"},{"issue":"10","key":"10.1016\/j.schres.2012.06.020_bb0420","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/archpsyc.1995.03950220087016","article-title":"Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors","volume":"52","author":"Pollm\u00e4cher","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2012.06.020_bb0425","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00004714-199610000-00011","article-title":"Effects of clozapine on plasma cytokine and soluble cytokine receptor levels","volume":"16","author":"Pollm\u00e4cher","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2012.06.020_bb0430","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/03630269.2010.484791","article-title":"Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone","volume":"34","author":"Pontikoglou","year":"2010","journal-title":"Hemoglobin"},{"issue":"8","key":"10.1016\/j.schres.2012.06.020_bb0435","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2012.06.020_bb0440","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/070674370805301211","article-title":"The incidence and characteristics of clozapine\u2010induced fever in a local psychiatric unit in Hong Kong","volume":"53","author":"Pui-yin Chung","year":"2008","journal-title":"Can. J. Psychiatry"},{"issue":"959","key":"10.1016\/j.schres.2012.06.020_bb0445","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/pgmj.2004.031161","article-title":"Clozapine, agranulocytosis, and benign ethnic neutropenia","volume":"81","author":"Rajagopal","year":"2005","journal-title":"Postgrad. Med. J."},{"issue":"2","key":"10.1016\/j.schres.2012.06.020_bb0450","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-0030-1249071","article-title":"Neutropenia induced by second generation antipsychotics: a prospective investigation","volume":"43","author":"Rettenbacher","year":"2010","journal-title":"Pharmacopsychiatry"},{"issue":"8","key":"10.1016\/j.schres.2012.06.020_bb0465","doi-asserted-by":"crossref","first-page":"976","DOI":"10.4088\/JCP.09m05024yel","article-title":"Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls","volume":"71","author":"Ronaldson","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2012.06.020_bb0455","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/00048674.2011.572852","article-title":"A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls","volume":"45","author":"Ronaldson","year":"2011","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2012.06.020_bb0460","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.schres.2011.01.017","article-title":"Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases","volume":"128","author":"Ronaldson","year":"2011","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2012.06.020_bb0610","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1006\/brbi.2001.0648","article-title":"Review of immunological and immunopathological findings in schizophrenia","volume":"15","author":"Rothermundt","year":"2001","journal-title":"Brain Behav. Immun."},{"issue":"4","key":"10.1016\/j.schres.2012.06.020_bb0475","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000067807","article-title":"The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon-gamma in vitro","volume":"46","author":"Rudolf","year":"2002","journal-title":"Neuropsychobiology"},{"issue":"8804","key":"10.1016\/j.schres.2012.06.020_bb0480","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/0140-6736(92)91625-I","article-title":"Rechallenge in clozapine-induced agranulocytosis","volume":"339","author":"Safferman","year":"1992","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.schres.2012.06.020_bb0485","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.schres.2012.06.020_bb0490","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1006\/brbi.2001.0647","article-title":"T-helper-1 and T-helper-2 responses in psychiatric disorders","volume":"15","author":"Schwarz","year":"2001","journal-title":"Brain Behav. Immun."},{"issue":"4","key":"10.1016\/j.schres.2012.06.020_bb0495","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/rheumatology\/kep450","article-title":"HLA-B27: what's new?","volume":"49","author":"Sheehan","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.schres.2012.06.020_bb0500","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.jaci.2007.02.010","article-title":"Eosinophilic disorders","volume":"119","author":"Simon","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.schres.2012.06.020_bb0505","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0306-9877(95)90062-4","article-title":"The macrophage-T-lymphocyte theory of schizophrenia: additional evidence","volume":"45","author":"Smith","year":"1995","journal-title":"Med. Hypotheses"},{"issue":"2","key":"10.1016\/j.schres.2012.06.020_bb0510","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0920-9964(99)00116-4","article-title":"Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist","volume":"42","author":"Song","year":"2000","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.schres.2012.06.020_bb0515","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0006-3223(93)90196-K","article-title":"Effects of clozapine on hematopoiesis and the cytokine system","volume":"34","author":"Sperner-Unterweger","year":"1993","journal-title":"Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2012.06.020_bb0520","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrneurol.2011.90","article-title":"Epilepsy: HLA alleles linked to carbamazepine hypersensitivity","volume":"7","author":"Striano","year":"2011","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.schres.2012.06.020_bb0525","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2567.2007.02574.x","article-title":"Histamine H4 receptor agonists have more activities than H4 agonism in antigen-specific human T-cell responses","volume":"121","author":"Sugata","year":"2007","journal-title":"Immunology"},{"issue":"1\u20132","key":"10.1016\/j.schres.2012.06.020_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2012.02.013","article-title":"Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation","volume":"197","author":"Suzuki","year":"2012","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0535","first-page":"59","article-title":"Neuroleptics modulate cytokine and reactive oxygen species production in blood leukocytes of healthy volunteers","volume":"52","author":"Szuster-Ciesielska","year":"2004","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"issue":"10","key":"10.1016\/j.schres.2012.06.020_bb0540","doi-asserted-by":"crossref","first-page":"880","DOI":"10.4088\/JCP.v63n1005","article-title":"Clozapine-induced fevers and 1-year clozapine discontinuation rate","volume":"63","author":"Tham","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2012.06.020_bb0545","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0009-9236(99)70072-X","article-title":"The cytotoxicity of clozapine metabolites: implications for predicting clozapine-induced agranulocytosis","volume":"65","author":"Tschen","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0550","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2370.1998.00091.x","article-title":"HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients","volume":"25","author":"Valevski","year":"1998","journal-title":"Eur. J. Immunogenet."},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0555","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00004714-200302000-00017","article-title":"Pancreatitis followed by pericardial effusion in an adolescent treated with clozapine","volume":"23","author":"Wehmeier","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0560","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00023210-200721010-00003","article-title":"Restarting clozapine after neutropenia: evaluating the possibilities and practicalities","volume":"21","author":"Whiskey","year":"2007","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.schres.2012.06.020_bb0565","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0022-3565(24)37177-0","article-title":"Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis","volume":"283","author":"Williams","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.schres.2012.06.020_bb0570","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/mol.58.1.207","article-title":"Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine","volume":"58","author":"Williams","year":"2000","journal-title":"Mol. Pharmacol."},{"issue":"8","key":"10.1016\/j.schres.2012.06.020_bb0575","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1176\/appi.ajp.160.8.1514","article-title":"Clozapine as a first treatment for schizophrenia","volume":"160","author":"Woerner","year":"2003","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2012.06.020_bb0580","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0022-3956(03)00018-9","article-title":"Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients","volume":"37","author":"Zimmermann","year":"2003","journal-title":"J. Psychiatr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996412003374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996412003374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T08:29:38Z","timestamp":1743841778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996412003374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":115,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0920996412003374"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2012.06.020","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}